Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...
Dubai: Dubai civil court has ordered a private medical center to pay Dh1.5 million in compensation to a patient after finding ...
Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have ...
Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...
Temple University is granted summary judgment on the ADA retaliation claim of an assistant professor suffering from myasthenia gravis who was denied tenure, because the discrimination complaint he ...
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today ...
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...
Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.
The Food and Drug Administration (FDA) has sent out 12 more Untitled Letters to pharma companies amid its ongoing crackdown ...
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo~71.8% ...
An update from Argenx Se ( (ARGX) ) is now available. On October 15, 2025, Argenx SE announced its participation in the 2025 AANEM Annual Meeting and MGFA Scientific Session, where it will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback